Skip to content
A8502Assembly2023-2024 SessionSame asS8040

Cover Biomarker Medical Testing

Official title

“Requires health insurance policies and medicaid to cover biomarker precision medical testing for certain purposes”

Sponsor Pamela J. HunterAD-128+2 co-sponsorsAffects Finance
Status
Signed by Governor
Impact
8/10
Significant
Outcome
Signed into law

Bill progress

Signed into law

What's happening

This bill expands and clarifies health insurance and Medicaid coverage of biomarker precision medical testing for diagnosis and treatment decisions, effective January 1, 2025.

Why it matters

  1. Broader Access to Biomarker Testing. By expanding insurance and Medicaid coverage to include biomarker precision medical testing for diagnosis, treatment, and ongoing monitoring, the bill enables more patients to access advanced and personalized medical care, particularly for complex diseases like cancer.

  2. Evidence Standards for Coverage. The bill loosens previous restrictions by allowing coverage if the utility of a biomarker test is recognized by FDA approval, Medicare coverage, clinical guidelines, or peer-reviewed medical literature—potentially leading to faster adoption of new and emerging tests that may not yet be included in all guidelines.

  3. Reducing Barriers to Care. The legislation requires coverage to be provided in ways that minimize disruptions in care, such as reducing the need for multiple biopsies, which can decrease patient discomfort, delay, and healthcare costs.

  4. Clarity and Consistency in Definitions. The bill standardizes and clarifies terminology around biomarkers and biomarker testing, which helps ensure insurers, providers, and patients have a shared understanding, likely reducing disputes over what is covered.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Patients with private insurance or Medicaid

    The bill would require coverage of qualifying biomarker precision medical testing for diagnosis and treatment decisions, while delaying the coverage requirements to January 1, 2025.

  • Health insurers

    The bill would revise the evidence standards for required testing coverage, expressly include qualifying peer-reviewed research and remove the requirement for a dedicated coverage-exception process.

  • Medicaid managed care plans

    The bill would remove the explicit requirement to provide biomarker testing at the same scope, duration and frequency as the Medicaid program.

  • Prescribing clinicians

    The bill would change the criteria supporting coverage of tests used to guide patient care and remove provisions guaranteeing patients and providers access to a coverage-exception process.

Headline styles

Cover Biomarker Medical Testing

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Pamela J. Hunter

Assembly Member · Assembly District 128

History

  1. Signed chap.29
  2. Delivered to governor
  3. Returned to assembly
  4. Passed senateVote 59–0
  5. 3rd reading cal.40
  6. Substituted for S8040
  7. Referred to rules
  8. Delivered to senate
  9. Passed assembly
  10. Ordered to third reading rules cal.4
  11. Rules report cal.4
  12. Reported
Show 3 earlier actions
  1. Reported referred to rules
  2. Reported referred to ways and means
  3. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

S8040Senate

Cover Biomarker Medical Testing

Senate Floor Calendar · Sponsor Roxanne J. Persaud

Impact 8 · Significant0% to pass

Full text

6 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

8502

IN ASSEMBLY

January 4, 2024

Introduced by M. of A. HUNTER -- read once and referred to the Committee on Insurance

AN ACT to amend the insurance law and the social services law, in relation to requiring health insurance policies and medicaid to cover biomarker precision medical testing for certain purposes; and to amend a chapter of the laws of 2023 amending the insurance law and the social services law relating to requiring health insurance policies and medicaid to cover biomarker testing for certain purposes, as proposed in legislative bills numbers S. 1196-A and A. 1673-A, in relation to the effectiveness thereof

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Paragraph 11-c of subsection (i) of section 3216 of the insurance law, as added by a chapter of the laws of 2023 amending the insurance law and the social services law relating to requiring health insurance policies and medicaid to cover biomarker testing for certain purposes, as proposed in legislative bills numbers S. 1196-A and A. 1673-A, is amended to read as follows:

(11-c) (A) Every policy which provides medical, major medical, or similar comprehensive-type coverage shall provide coverage for biomarker precision medical testing for the purposes of diagnosis, treatment, or appropriate management of, or ongoing monitoring [of a covered person's] to guide treatment decisions for, an insured's disease or condition when [the test provides clinical utility to the patient as demonstrated by medical and scientific evidence, including, but not limited to] one or more of the following recognizes the efficacy and appropriateness of biomarker precision medical testing for diagnosis, treatment, appropriate management, or guiding treatment decisions for an insured's disease or condition:

(i) labeled indications for a test approved or cleared by the federal food and drug administration or indicated tests for a food and drug administration approved drug;

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD02625-08-4

(ii) centers for medicare and medicaid services national coverage determinations [and] or medicare administrative contractor local coverage determinations; [or]

(iii) nationally recognized clinical practice guidelines [such as, but not limited to, those of the national comprehensive cancer network or the American society of clinical oncology.]; or

(iv) peer-reviewed literature and peer-reviewed scientific studies published in or accepted for publication by medical journals that meet nationally recognized requirements for scientific manuscripts and that submit most of their published articles for review by experts who are not part of the editorial staff.

(B) Such coverage shall be provided in a manner that shall limit disruptions in care including the need for multiple biopsies or biospecimen samples.

(C) [The covered person and prescribing practitioner shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy provided pursuant to the provisions of this paragraph. Such process shall be made readily accessible on the website of the insurer.

(D)] As used in this paragraph, the following terms shall have the following meanings:

(i) "Biomarker" means a [defined] characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. [Molecular, histologic, radiographic, or physiologic characteristics are types of biomarkers. A biomarker is not an assessment of how a patient feels, functions, or survives.]

(ii) "Biomarker precision medical testing" means the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes but is not limited to single-analyte tests and multi-plex panel tests performed at a participating in-network laboratory facility that is either CLIA certified or CLIA waived by the federal food and drug administration.

(iii) ["Clinical utility" means the test result provides information that is used in the formulation of a treatment or monitoring strategy that informs a patient's outcome and impacts the clinical decision.

(iv)] "Nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines informed by a systematic review of evidence and an assessment of the benefits, and risks of alternative care options intended to optimize patient care developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict of interest policy.

§ 2. Paragraph 11-c of subsection (l) of section 3221 of the insurance law, as added by a chapter of the laws of 2023 amending the insurance law and the social services law relating to requiring health insurance policies and medicaid to cover biomarker testing for certain purposes, as proposed in legislative bills numbers S. 1196-A and A. 1673-A, is amended to read as follows:

(11-c) (A) Every insurer delivering a group or blanket policy or issuing a group or blanket policy for delivery in this state that provides coverage for medical, major medical, or similar comprehensive-type coverage shall provide coverage for biomarker precision medical testing for the purposes of diagnosis, treatment, or appropriate management of, or ongoing monitoring [of a covered person's] to guide treatment decisions for, an insured's disease or condition when [the test provides clinical utility to the patient as demonstrated by medical and scientific evidence, including, but not limited to] one or more of the following recognizes the efficacy and appropriateness of biomarker precision medical testing for diagnosis, treatment, appropriate management, or guiding treatment decisions for an insured's disease or condition:

(i) labeled indications for a test approved or cleared by the federal food and drug administration or indicated tests for a food and drug administration approved drug;

(ii) centers for medicare and medicaid services national coverage determinations [and] or medicare administrative contractor local coverage determinations; [or]

(iii) nationally recognized clinical practice guidelines [including, but not limited to, those of the national comprehensive cancer network or the American society of clinical oncology.]; or

(iv) peer-reviewed literature and peer-reviewed scientific studies published in or accepted for publication by medical journals that meet nationally recognized requirements for scientific manuscripts and that submit most of their published articles for review by experts who are not part of the editorial staff.

(B) Such coverage shall be provided in a manner that shall limit disruptions in care including the need for multiple biopsies or biospecimen samples.

(C) [The covered person and prescribing practitioner shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy provided pursuant to the provisions of this paragraph. Such process shall be made readily accessible on the website of the insurer.

(D)] As used in this paragraph, the following terms shall have the following meanings:

(i) "Biomarker" means a [defined] characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. [Molecular, histologic, radiographic, or physiologic characteristics are types of biomarkers. A biomarker is not an assessment of how a patient feels, functions, or survives.]

(ii) "Biomarker precision medical testing" means the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes but is not limited to single-analyte tests and multi-plex panel tests performed at a participating in-network laboratory facility that is either CLIA certified or CLIA waived by the federal food and drug administration.

(iii) ["Clinical utility" means the test result provides information that is used in the formulation of a treatment or monitoring strategy that informs a patient's outcome and impacts the clinical decision.

(iv)] "Nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines informed by a systematic review of evidence and an assessment of the benefits, and risks of alternative care options intended to optimize patient care developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict of interest policy.

§ 3. Subsection (p-1) of section 4303 of the insurance law, as added by a chapter of the laws of 2023 amending the insurance law and the social services law relating to requiring health insurance policies and medicaid to cover biomarker testing for certain purposes, as proposed in legislative bills numbers S. 1196-A and A. 1673-A, is amended to read as follows:

(p-1) (1) A medical expense indemnity corporation, a hospital service corporation or a health service corporation that provides coverage for medical, major medical, or similar comprehensive-type coverage shall provide coverage for biomarker precision medical testing for the purposes of diagnosis, treatment, or appropriate management of, or ongoing monitoring [of a covered person's] to guide treatment decisions for, an insured's disease or condition when [the test provides clinical utility to the patient as demonstrated by medical and scientific evidence, including, but not limited to] one or more of the following recognizes the efficacy and appropriateness of biomarker precision medical testing for diagnosis, treatment, appropriate management, or guiding treatment decisions for an insured's disease or condition:

(A) labeled indications for a test approved or cleared by the federal food and drug administration or indicated tests for a food and drug administration approved drug;

(B) centers for medicare and medicaid services national coverage determinations [and] or medicare administrative contractor local coverage determinations; [or]

(C) nationally recognized clinical practice guidelines [such as, but not limited to, those of the national comprehensive cancer network or the American society of clinical oncology.]; or

(D) peer-reviewed literature and peer-reviewed scientific studies published in or accepted for publication by medical journals that meet nationally recognized requirements for scientific manuscripts and that submit most of their published articles for review by experts who are not part of the editorial staff.

(2) Such coverage shall be provided in a manner that shall limit disruptions in care including the need for multiple biopsies or biospecimen samples.

(3) [The covered person and prescribing practitioner shall have access to a clear, readily accessible, and convenient process to request an exception to a coverage policy provided pursuant to the provisions of this subsection. Such process shall be made readily accessible on the website of the insurer.

(4)] As used in this subsection, the following terms shall have the following meanings:

(A) "Biomarker" means a [defined] characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. [Molecular, histologic, radiographic, or physiologic characteristics are types of biomarkers. A biomarker is not an assessment of how a patient feels, functions, or survives.]

(B) "Biomarker precision medical testing" means the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes but is not limited to single-analyte tests and multi-plex panel tests performed at a participating in-network laboratory facility that is either CLIA certified or CLIA waived by the federal food and drug administration.

(C) ["Clinical utility" means the test result provides information that is used in the formulation of a treatment or monitoring strategy that informs a patient's outcome and impacts the clinical decision.

(D)] "Nationally recognized clinical practice guidelines" means evidence-based clinical practice guidelines informed by a systematic review of evidence and an assessment of the benefits, and risks of alternative care options intended to optimize patient care developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict of interest policy.

§ 4. Paragraph (mm) of subdivision 2 of section 365-a of the social services law, as added by a chapter of the laws of 2023 amending the insurance law and the social services law relating to requiring health insurance policies and medicaid to cover biomarker testing for certain purposes, as proposed in legislative bills numbers S. 1196-A and A. 1673-A, is amended to read as follows:

(mm) (i) biomarker precision medical testing for the purposes of diagnosis, treatment, or appropriate management of, or ongoing monitoring [of] to guide treatment decisions for, a recipient's disease or condition when [the test provides clinical utility to the patient as demonstrated by medical and scientific evidence, including, but not limited to] one or more of the following recognizes the efficacy and appropriateness of biomarker precision medical testing for diagnosis, treatment, appropriate management, or guiding treatment decisions for a recipient's disease or condition:

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.